Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

Summary

The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start

2009-06

Primary completion

2011-05

Completion

2011-05

Drugs

Indications